24.02.2016 Bayer Aktiengesellschaft  DE000BAY0017

DGAP-Adhoc: Bayer Aktiengesellschaft: Werner Baumann to succeed Dr. Marijn Dekkers as Chairman of the Board of Management of Bayer AG


 
Bayer Aktiengesellschaft / Key word(s): Change of Personnel 24.02.2016 10:58 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Leverkusen, February 24, 2016 Effective May 1, 2016, Werner Baumann will become the new Chairman of the Board of Management of Bayer AG. This was decided by the company's Supervisory Board at its meeting today. The current CEO of Bayer AG, Dr. Marijn Dekkers, proposed to the Supervisory Board that his contract be dissolved effective April 30, 2016, following the Annual Stockholders' Meeting. The Supervisory Board approved this proposal. Following rapid implementation of the realignment under Dr. Dekkers' leadership, Bayer is now entering a new era as a pure Life Science company. That is why the Supervisory Board believes this is now the right time to hand on responsibility for managing the company. Dekkers' contract was originally scheduled to run until December 31, 2016. At the present time, Baumann is the Board member with responsibility for Strategy and Portfolio Management. He will retain these functions in the future. Going forward, the Board of Management of Bayer AG will comprise seven members instead of eight. Contact: Mr. Peter Dahlhoff, Bayer AG, Investor Relations, Phone: +49-214-30-33022, e-mail: [email protected], Fax: 0214-30-96-33022 --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: Forward-Looking Statements This ad-hoc announcement may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. 24.02.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Bayer Aktiengesellschaft Kaiser-Wilhelm-Allee 1 51373 Leverkusen Germany Phone: +49 (0)214 30-81 013 Fax: +49 (0)21430-9681013 E-mail: Internet: www.bayer.com ISIN: DE000BAY0017 WKN: BAY001 Indices: DAX, EURO STOXX 50, Stoxx 50 Listed: Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Hanover, Munich, Stuttgart; Terminbörse EUREX; Madrid, Luxemburg End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 35.015,00 39.586,00 43.545,00 41.400,00 44.081,00 50.739,00 47.637,00
EBITDA1,2 8.563,00 9.695,00 9.554,00 -2.910,00 6.409,00 13.515,00 10.632,00
EBITDA-Marge3 24,46 24,49 21,94 -7,03 14,54 26,64
EBIT1,4 5.903,00 3.454,00 4.189,00 -16.169,00 3.353,00 7.012,00 6.460,00
EBIT-Marge5 16,86 8,73 9,62 -39,06 7,61 13,82 13,56
Jahresüberschuss1 8.094,00 1.711,00 4.110,00 -10.487,00 1.022,00 4.166,00 -2.942,00
Netto-Marge6 23,12 4,32 9,44 -25,33 2,32 8,21 -6,18
Cashflow1,7 8.134,00 7.917,00 8.207,00 4.903,00 5.089,00 7.093,00 5.117,00
Ergebnis je Aktie8 8,41 1,80 4,17 -10,68 1,02 4,22 -2,99
Dividende8 2,80 2,80 2,80 2,00 2,00 2,40 2,70
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
Bayer
WKN Kurs in € Einschätzung Börsenwert in Mio. €
BAY001 20,155 Verkaufen 19.800,76
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
11,86 23,22 0,51 10,28
KBV KCV KUV EV/EBITDA
0,60 3,87 0,42 5,92
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
Hauptversammlung
2,40 0,11 0,55 25.04.2025
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
13.05.2025 06.08.2024 12.11.2024 05.03.2025
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-24,11% -25,62% -40,07% -40,73%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Bayer Aktiengesellschaft  ISIN: DE000BAY0017 können Sie bei EQS abrufen


Gesundheit , BAY001 , BAYN , XETR:BAYN